Overview

Role of Immune Responses After Acute Myocardial Infarction

Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The fascinating role of lymphocyte subtypes in the development of coronary artery disease may be a new strategic target for understanding and therapy of acute myocardial infarction. The determinants of cell viability are unknown, postulating that they arise from factors not only related to microcirculation or energy expenditure, but also to inflammatory and immune responses. Furthermore, the intense mobilization of progenitor cells secondary to myocardial infarction triggers large lymphocyte proliferation that colonizes plaques in development, contributing to recurrent ischemic outcomes. This project aims to evaluate the immune and metabolic mechanisms involved in the recovery of the ischemic myocardium and coronary disease progression.
Phase:
Phase 4
Details
Lead Sponsor:
Federal University of São Paulo
Collaborators:
FAPESP - Fundação de Apoio à Pesquisa do Estado de São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Treatments:
Clopidogrel
Rosuvastatin Calcium
Simvastatin
Ticagrelor
Ticlopidine